Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) reached a new 52-week high on Monday . The stock traded as high as $55.00 and last traded at $54.86, with a volume of 4454 shares changing hands. The stock had previously closed at $52.80.

A number of analysts have issued reports on the stock. Svb Leerink upgraded shares of Deciphera Pharmaceuticals from an “underperform” rating to a “market perform” rating and boosted their price target for the stock from $29.00 to $34.00 in a research note on Tuesday, October 29th. JMP Securities raised their price objective on shares of Deciphera Pharmaceuticals from $45.00 to $54.00 and gave the company a “market outperform” rating in a research note on Tuesday, November 5th. Leerink Swann upgraded shares of Deciphera Pharmaceuticals from an “underperform” rating to a “market perform” rating in a report on Tuesday, October 29th. SunTrust Banks lifted their price objective on shares of Deciphera Pharmaceuticals to $60.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. Finally, Guggenheim upped their target price on shares of Deciphera Pharmaceuticals from $44.00 to $66.00 and gave the stock a “buy” rating in a research note on Tuesday, August 13th. One analyst has rated the stock with a sell rating, four have given a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $49.31.

The business has a 50-day simple moving average of $44.62 and a 200-day simple moving average of $32.30. The company has a market cap of $2.70 billion, a price-to-earnings ratio of -19.36 and a beta of 1.94.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its quarterly earnings data on Monday, November 4th. The company reported ($1.28) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.19) by ($0.09). On average, equities research analysts anticipate that Deciphera Pharmaceuticals Inc will post -4.25 EPS for the current fiscal year.

In related news, Director Michael Douglas Taylor sold 22,500 shares of the business’s stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $34.97, for a total transaction of $786,825.00. Also, CFO Thomas Patrick Kelly sold 11,250 shares of the business’s stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $34.97, for a total transaction of $393,412.50. In the last ninety days, insiders sold 263,281 shares of company stock worth $12,181,518. 7.02% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Metropolitan Life Insurance Co NY acquired a new position in shares of Deciphera Pharmaceuticals during the 3rd quarter worth about $194,000. Man Group plc purchased a new position in shares of Deciphera Pharmaceuticals in the 3rd quarter valued at about $1,079,000. Redmile Group LLC increased its holdings in shares of Deciphera Pharmaceuticals by 115.0% in the 3rd quarter. Redmile Group LLC now owns 4,780,898 shares of the company’s stock valued at $162,264,000 after acquiring an additional 2,557,522 shares during the last quarter. Voloridge Investment Management LLC acquired a new stake in shares of Deciphera Pharmaceuticals during the 3rd quarter worth about $973,000. Finally, Barclays PLC raised its position in shares of Deciphera Pharmaceuticals by 250.2% during the 3rd quarter. Barclays PLC now owns 33,548 shares of the company’s stock worth $1,138,000 after acquiring an additional 23,967 shares in the last quarter. 69.45% of the stock is owned by institutional investors.

Deciphera Pharmaceuticals Company Profile (NASDAQ:DCPH)

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.

Read More: What is Net Asset Value (NAV)?

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.